Physician profile
Viola Hoxha
NPI 1013533645
$4,469.44
in general payments reported to CMS, 2019-2025
28 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2023: $557 · 2024: $2,063 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,232 · Education: $1.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,231.85 |
| Education | $1.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $864.08 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $776.41 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $434.81 | 2023-2025 | Sunosi, Auvelity |
| Lilly USA, LLC | $434.59 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $422.89 | 2023-2025 | |
| Glaxosmithkline, LLC. | $221.48 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $189.61 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Tris Pharma INC | $151.41 | 2024 | Dyanavel Xr |
| Exact Sciences Corporation | $137.93 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $137.50 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $85.63 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $75.71 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $68.75 | 2024-2025 | |
| Astellas Pharma US INC | $62.11 | 2025 | Veozah |
| Dexcom, INC. | $51.88 | 2024 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.25 | 2023-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.19 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $35.67 | 2025 | |
| Corium, LLC | $34.90 | 2024 | Azstarys |
| Becton, Dickinson and Company | $31.93 | 2025 | Bd Onclarity |
| Hologic Sales and Service, LLC | $28.35 | 2025 | Aptima |
| Lundbeck LLC | $25.88 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $24.80 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.30 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $20.19 | 2023 | Rexulti |
| Bausch Health US, LLC | $16.81 | 2025 | Aplenzin |
| Currax Pharmaceuticals LLC | $15.12 | 2025 | Contrave |
| Neos Therapeutics, LP | $14.26 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viola Hoxha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.